Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated with Cyclic Vomiting Syndrome

American Journal of Gastroenterology

Volumn 112, Issue 6, 2017, Pages 933-939

  Wasilewski, Andrzej ^a   Lewandowska, Urszula ^a   Mosinska, Paula ^a   Watala, Cezary ^a   Storr, Martin ^b,c   Fichna, Jakub ^a   Venkatesan, Thangam ^d  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Center of Endoscopy   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR TYPE 1; CANNABINOID RECEPTOR TYPE 2; CANNABIS; FATTY ACID AMIDASE; LORAZEPAM; MU OPIATE RECEPTOR; ONDANSETRON; PROCHLORPERAZINE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; CANNABINOID 1 RECEPTOR; CNR1 PROTEIN, HUMAN;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CYCLIC VOMITING SYNDROME; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; PRIORITY JOURNAL; RELATIVE; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING; GENETICS; MIDDLE AGED; QUESTIONNAIRE; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; SURVEYS AND QUESTIONNAIRES; VOMITING; YOUNG ADULT;

EID: 85016129782     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2017.73     Document Type: Article

References (33)

1. Yang HR. Recent concepts on cyclic vomiting syndrome in children. J Neurogastroenterol Motil 2010; 16: 139-47.
2. Abu-Arafeh I, Russell G. Prevalence and clinical features of abdominal migraine compared with those of migraine headache. Arch Dis Child 1995; 72: 413-7.
3. Abu-Arafeh I, Russell G. Cyclical vomiting syndrome in children: a population-based study. J Pediatr Gastroenterol Nutr 1995; 21: 454-8.
4. Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol 1999; 94: 2855-60.
5. Prakash C, Staiano A, Rothbaum RJ et al. Similarities in cyclic vomiting syndrome across age groups. Am J Gastroenterol 2001; 96: 684-8.
6. Fleisher DR, Gornowicz B, Adams K et al. Cyclic Vomiting Syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med 2005; 3: 20.
7. Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 2006; 129: 3-16.
8. Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology 2016; 151: 252-66.
9. Venkatesan T, Zadvornova Y, Raff H et al. Endocannabinoid-related lipids are increased during an episode of cyclic vomiting syndrome. Neurogastroenterol Motil 2016; 28: 1409-18.
10. Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral mu-opioid receptor antagonist methylnaltrexone. Drugs 2013; 73: 1297-306.
11. Hejazi RA, Reddymasu SC, Namin F et al. Effi cacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol 2010; 44: 18-21.
12. Boles RG, Lovett-Barr MR, Preston A et al. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol 2010; 10: 10.
13. Venkatesan T, Zaki EA, Kumar N et al. Quantitative pedigree analysis and mitochondrial DNA sequence variants in adults with cyclic vomiting syndrome. BMC Gastroenterol 2014; 14: 181.
14. 1000 Genomes Project Consortium. Abecasis GR, Auton A et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65.
15. Zaki EA, Freilinger T, Klopstock T et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia 2009; 29: 719-28.
16. Chakrabarti B, Baron-Cohen S. Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces. Mol Autism 2011; 2: 10.
17. Hartman CA, Hopfer CJ, Haberstick B et al. The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug Alcohol Depend 2009; 104: 11-16.
18. Hopfer CJ, Young SE, Purcell S et al. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 895-901.
19. Agrawal A, Wetherill L, Dick DM et al. Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 736-40.
20. Marcos M, Pastor I, de la Calle C et al. Cannabinoid receptor 1 gene is associated with alcohol dependence. Alcohol Clin Exp Res 2012; 36: 267-71.
21. Mitjans M, Serretti A, Fabbri C et al. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology (Berl) 2013; 227: 509-19.
22. Russo P, Strazzullo P, Cappuccio FP et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007; 92: 2382-6.
23. Bond C, LaForge KS, Tian M et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-13.
24. Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics 2013; 14: 813-24.
25. Ren ZY, Xu XQ, Bao YP et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician 2015; 18: 131-52.
26. Kroslak T, LaForge KS, Gianotti RJ et al. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103: 77-87.
27. Zhang Y, Wang D, Johnson AD et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280: 32618-24.
28. Li BU, Murray RD, Heitlinger LA et al. Is cyclic vomiting syndrome related to migraine? J Pediatr 1999; 134: 567-72.
29. Stickler GB. Relationship between cyclic vomiting syndrome and migraine. Clin Pediatr 2005; 44: 505-8.
30. Li BU, Lefevre F, Chelimsky GG et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47: 379-93.
31. Sunku B, Li BUK. Cyclic vomiting syndrome. In: Guandalini S (ed). Textbook of Pediatric Gastroenterology and Nutrition, Taylor and Francis Group: London, UK, 2004, pp 289-302.
32. Mitjans M, Gasto C, Catalan R et al. Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes. J Psychopharmacol 2012; 26: 1391-8.
33. Hamdani N, Tabeze JP, Ramoz N et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008; 18: 34-40.